GR3030545T3 - Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants - Google Patents

Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants

Info

Publication number
GR3030545T3
GR3030545T3 GR990401622T GR990401622T GR3030545T3 GR 3030545 T3 GR3030545 T3 GR 3030545T3 GR 990401622 T GR990401622 T GR 990401622T GR 990401622 T GR990401622 T GR 990401622T GR 3030545 T3 GR3030545 T3 GR 3030545T3
Authority
GR
Greece
Prior art keywords
carnitine
cyclosporin
immunosuppressants
derivatives
reducing
Prior art date
Application number
GR990401622T
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of GR3030545T3 publication Critical patent/GR3030545T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GR990401622T 1995-01-20 1999-06-16 Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants GR3030545T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Publications (1)

Publication Number Publication Date
GR3030545T3 true GR3030545T3 (en) 1999-10-29

Family

ID=11402949

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401622T GR3030545T3 (en) 1995-01-20 1999-06-16 Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants

Country Status (13)

Country Link
US (2) US5955424A (el)
EP (1) EP0722724B1 (el)
JP (1) JPH08231390A (el)
KR (1) KR100443730B1 (el)
AT (1) ATE177946T1 (el)
CA (1) CA2167456A1 (el)
DE (1) DE69508551T2 (el)
DK (1) DK0722724T3 (el)
ES (1) ES2130509T3 (el)
GR (1) GR3030545T3 (el)
IT (1) IT1277147B1 (el)
TW (1) TW445145B (el)
ZA (1) ZA96431B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
IT1306179B1 (it) 1999-07-28 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
DE60111858T2 (de) * 2000-10-12 2006-04-20 Pharma Mar, S.A., Tres Cantos BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
JPH01213258A (ja) * 1988-02-23 1989-08-28 Kyowa Hakko Kogyo Co Ltd カルニチンおよびカルニチンアミドの精製法

Also Published As

Publication number Publication date
EP0722724B1 (en) 1999-03-24
EP0722724A1 (en) 1996-07-24
ZA96431B (en) 1996-08-08
JPH08231390A (ja) 1996-09-10
US5955424A (en) 1999-09-21
DE69508551T2 (de) 1999-09-02
ITRM950037A0 (it) 1995-01-20
CA2167456A1 (en) 1996-07-21
ATE177946T1 (de) 1999-04-15
TW445145B (en) 2001-07-11
ES2130509T3 (es) 1999-07-01
KR100443730B1 (ko) 2004-10-14
ITRM950037A1 (it) 1996-07-20
KR960029314A (ko) 1996-08-17
IT1277147B1 (it) 1997-11-04
DE69508551D1 (de) 1999-04-29
US5958941A (en) 1999-09-28
DK0722724T3 (da) 1999-10-11

Similar Documents

Publication Publication Date Title
GR3030545T3 (en) Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
CA2235375A1 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of a .mu. opioid agonist and a .kappa.-2 opioid agonist
CA2183655A1 (en) 4-polycyclic amino-substituted quinazoline derivatives
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2209001A1 (en) Hydrophobic taxane derivatives
MX9701013A (es) Formulaciones oftalmicos topicas que contienen derivador de doxepina para tratamiento de enfermedades oculares alergicas.
IL109615A (en) Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
EP0630898A4 (en) MEDICINE FOR THROMBOZYTOPENIA.
IL123551A0 (en) Tricyclic erythromycin derivatives
CA2053826A1 (en) Pharmaceutical compositions active in the therapy of neurological affections in aids patients
BG103372A (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ANTI-Xa- ACTIVITY BELONGING COMPOUND AND AN ANTAGONIST COMPOUND OF THROMBOCYTE AGGREGATION
EP0485636A4 (en) Indole derivative
EP0620004A4 (en) MEDICAL COMPOSITION.
EP0522173A4 (en) 4-desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable salt thereof
UA29435C2 (uk) Похідні 3бета-алкенілпенаму та їх фармацевтично прийнятні солі
ZA9110037B (en) The use of acetyl l-carnitine in the therapeutic treatment of coma and pharmacological compositions useful in such treatment
IL117971A (en) Pharmaceutical compositions containing olanzapine for treating dyskinesias
CA2179733A1 (en) Anticonvulsant pseudofructopyranose sulfamates
ZA892188B (en) Peptide derivatives
CA2190837A1 (en) Transdermal delivery of anti-epileptic drugs
EP0855398A4 (en) SESQUITERPEN DERIVATIVES WITH ANTIVITAL ACTIVITY
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
GB9420748D0 (en) 1,5 benzodiazepine derivatives